Can spironolactone cause abnormal vaginal bleeding and irregular menstrual periods?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Spironolactone Commonly Causes Menstrual Irregularities and Abnormal Vaginal Bleeding

Menstrual irregularities are the most common side effect of spironolactone, occurring in 15-30% of patients, and this effect is dose-dependent. 1

Mechanism and Incidence

Spironolactone causes menstrual irregularities through its antagonistic effects on both androgen and progesterone receptors. The bleeding patterns typically manifest as:

  • Midcycle vaginal bleeding (metrorrhagia)
  • Irregular menstrual cycles
  • Shortened cycles (as short as 14 days in some cases)

The risk increases substantially with higher doses, with a relative risk of 4.12 (95% CI 3.27-5.19) in women receiving 200mg/day compared to lower doses 1. At the commonly prescribed starting dose of 100mg/day, menstrual irregularities still occur in approximately 15-30% of patients 1, 2.

Clinical Evidence

Multiple studies document this effect:

  • In one prospective study, 56% of women on 100mg twice daily (200mg total) developed metrorrhagia with 14-day cycles 3
  • Another study found 50% of women on spironolactone experienced irregular bleeding, while none in the comparison group (flutamide) had menstrual irregularities 4
  • Research shows spironolactone reduces serum estradiol levels and endometrial thickness, with women experiencing bleeding having significantly lower estradiol values 5

Management Strategy

The concomitant use of combined oral contraceptives (COC) or hormonal intrauterine devices can minimize the incidence of menstrual irregularities 1, 2. This approach serves dual purposes:

  1. Regulates menstrual cycles and prevents breakthrough bleeding
  2. Provides necessary contraception (spironolactone is pregnancy category C with potential for feminization of male fetuses) 1, 6

Practical Dosing Recommendations

  • Start at 50mg twice daily (100mg total) on days 4-21 of the menstrual cycle rather than continuous dosing 3
  • If starting at 100mg daily continuously, warn patients about the 15-30% risk of irregular bleeding
  • Consider adding cyclical estrogen/progesterone therapy if breakthrough bleeding occurs on continuous spironolactone 3
  • If 200mg/day is needed for therapeutic effect, expect menstrual irregularities in up to 50% of patients

Important Caveats

While menstrual irregularities are common and bothersome, they are not dangerous 3. However, they may be intolerable enough to require:

  • Dose reduction
  • Addition of hormonal contraception
  • Medication discontinuation in some cases

The FDA label confirms spironolactone's effects on reproductive hormones, noting it can cause "endocrine dysfunction" and affect sex hormone production 6. These effects are reversible upon discontinuation.

Bottom line: Counsel all women starting spironolactone about the 15-30% risk of menstrual irregularities, recommend concomitant COC use to minimize this effect, and consider starting with cyclical rather than continuous dosing if breakthrough bleeding is a concern.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.